Elise Ishida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elise Ishida has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
- Jacqueline M. Achkar
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA
3 shared publications - Mark Connors
National Institute of Allergy and Infectious Diseases
3 shared publications - Trevor Griesman
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104
3 shared publications Baoshan Zhang
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD 20892, USA
2 shared publications- Bihui Hilda Ye
Albert Einstein College of Medicine, Bronx, New York, United States
2 shared publications Byong H. Kang
HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA
2 shared publications
Latest Publications
- 2 July 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (7) , 1394-1408
Tailoring the Methods of Conjugation and Characterization for a Replication-Competent, Live, Viral Vector
Optimized functionalization of virus particles can expand the toolbox available for the development of viral vector-based therapies. However, labeling of a large, complex, and biologically active particle introduces distinct technological challenges for subsequent purification and characterization steps. Moreover, the process of labeling and purification, and even the label itself, may have an unwanted impact on the particle's biological activity. Herein, we present a comprehensive series of steps for conjugation, purification, and characterization that are adapted from traditional biologics (e.g., monoclonal antibodies) and apply them to the replication-competent rhabdovirus VSV-GP-GFP. By confirming purity and quantifying the average degree of labeling (DoL), we tailored the label/particle ratio to generate tool viruses suitable for downstream applications in nonclinical and clinical development. These methods will enhance the development of viral vector therapies and hasten their delivery to patients in need.
- 2 July 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (7) , 1394-1408
Tailoring the Methods of Conjugation and Characterization for a Replication-Competent, Live, Viral Vector
Optimized functionalization of virus particles can expand the toolbox available for the development of viral vector-based therapies. However, labeling of a large, complex, and biologically active particle introduces distinct technological challenges for subsequent purification and characterization steps. Moreover, the process of labeling and purification, and even the label itself, may have an unwanted impact on the particle's biological activity. Herein, we present a comprehensive series of steps for conjugation, purification, and characterization that are adapted from traditional biologics (e.g., monoclonal antibodies) and apply them to the replication-competent rhabdovirus VSV-GP-GFP. By confirming purity and quantifying the average degree of labeling (DoL), we tailored the label/particle ratio to generate tool viruses suitable for downstream applications in nonclinical and clinical development. These methods will enhance the development of viral vector therapies and hasten their delivery to patients in need.
- Open Access
- 13 December 2023
- Published by Elsevier in EBioMedicine
- Vol. 99, 104897
Mucosal and systemic antigen-specific antibody responses correlate with protection against active tuberculosis in nonhuman primates
- 13 December 2023
- Published by Elsevier in EBioMedicine
- Vol. 99, 104897
Open AccessMucosal and systemic antigen-specific antibody responses correlate with protection against active tuberculosis in nonhuman primates
- Open Access
- 12 October 2021
- Published by Springer Nature in Communications Biology
- Vol. 4 (1) , 1-13
Monoclonal antibodies from humans with Mycobacterium tuberculosis exposure or latent infection recognize distinct arabinomannan epitopes
The surface polysacharide arabinomannan (AM) and related glycolipid lipoarabinomannan (LAM) play critical roles in tuberculosis pathogenesis. Human antibody responses to AM/LAM are heterogenous and knowledge of reactivity to specific glycan epitopes at the monoclonal level is limited, especially in individuals who can control M. tuberculosis infection. We generated human IgG mAbs to AM/LAM from B cells of two asymptomatic individuals exposed to or latently infected with M. tuberculosis. Here, we show that two of these mAbs have high affinity to AM/LAM, are non-competing, and recognize different glycan epitopes distinct from other anti-AM/LAM mAbs reported. Both mAbs recognize virulent M. tuberculosis and nontuberculous mycobacteria with marked differences, can be used for the detection of urinary LAM, and can detect M. tuberculosis and LAM in infected lungs. These mAbs enhance our understanding of the spectrum of antibodies to AM/LAM epitopes in humans and are valuable for tuberculosis diagnostic and research applications.
- 12 October 2021
- Published by Springer Nature in Communications Biology
- Vol. 4 (1) , 1-13
Open AccessMonoclonal antibodies from humans with Mycobacterium tuberculosis exposure or latent infection recognize distinct arabinomannan epitopes
The surface polysacharide arabinomannan (AM) and related glycolipid lipoarabinomannan (LAM) play critical roles in tuberculosis pathogenesis. Human antibody responses to AM/LAM are heterogenous and knowledge of reactivity to specific glycan epitopes at the monoclonal level is limited, especially in individuals who can control M. tuberculosis infection. We generated human IgG mAbs to AM/LAM from B cells of two asymptomatic individuals exposed to or latently infected with M. tuberculosis. Here, we show that two of these mAbs have high affinity to AM/LAM, are non-competing, and recognize different glycan epitopes distinct from other anti-AM/LAM mAbs reported. Both mAbs recognize virulent M. tuberculosis and nontuberculous mycobacteria with marked differences, can be used for the detection of urinary LAM, and can detect M. tuberculosis and LAM in infected lungs. These mAbs enhance our understanding of the spectrum of antibodies to AM/LAM epitopes in humans and are valuable for tuberculosis diagnostic and research applications.
- 1 March 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (5)
A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity
BACKGROUND. To understand the features of a replicating vaccine that might drive potent and durable immune responses to transgene-encoded antigens, we tested a replication-competent adenovirus type 4 encoding influenza virus H5 HA (Ad4-H5-Vtn) administered as an oral capsule or via tonsillar swab or nasal spray. METHODS. Viral shedding from the nose, mouth, and rectum was measured by PCR and culturing. H5-specific IgG and IgA antibodies were measured by bead array binding assays. Serum antibodies were measured by a pseudovirus entry inhibition, microneutralization, and HA inhibition assays. RESULTS. Ad4-H5-Vtn DNA was shed from most upper respiratory tract–immunized (URT-immunized) volunteers for 2 to 4 weeks, but cultured from only 60% of participants, with a median duration of 1 day. Ad4-H5-Vtn vaccination induced increases in H5-specific CD4+ and CD8+ T cells in the peripheral blood as well as increases in IgG and IgA in nasal, cervical, and rectal secretions. URT immunizations induced high levels of serum neutralizing antibodies (NAbs) against H5 that remained stable out to week 26. The duration of viral shedding correlated with the magnitude of the NAb response at week 26. Adverse events (AEs) were mild, and peak NAb titers were associated with overall AE frequency and duration. Serum NAb titers could be boosted to very high levels 2 to 5 years after Ad4-H5-Vtn vaccination with recombinant H5 or inactivated split H5N1 vaccine. CONCLUSION. Replicating Ad4 delivered to the URT caused prolonged exposure to antigen, drove durable systemic and mucosal immunity, and proved to be a promising platform for the induction of immunity against viral surface glycoprotein targets. TRIAL REGISTRATION. ClinicalTrials.gov NCT01443936 and NCT01806909. FUNDING. Intramural and Extramural Research Programs of the NIAID, NIH (U19 AI109946) and the Centers of Excellence for Influenza Research and Surveillance (CEIRS), NIAID, NIH (contract HHSN272201400008C).
- 1 March 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (5)
A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity
BACKGROUND. To understand the features of a replicating vaccine that might drive potent and durable immune responses to transgene-encoded antigens, we tested a replication-competent adenovirus type 4 encoding influenza virus H5 HA (Ad4-H5-Vtn) administered as an oral capsule or via tonsillar swab or nasal spray. METHODS. Viral shedding from the nose, mouth, and rectum was measured by PCR and culturing. H5-specific IgG and IgA antibodies were measured by bead array binding assays. Serum antibodies were measured by a pseudovirus entry inhibition, microneutralization, and HA inhibition assays. RESULTS. Ad4-H5-Vtn DNA was shed from most upper respiratory tract–immunized (URT-immunized) volunteers for 2 to 4 weeks, but cultured from only 60% of participants, with a median duration of 1 day. Ad4-H5-Vtn vaccination induced increases in H5-specific CD4+ and CD8+ T cells in the peripheral blood as well as increases in IgG and IgA in nasal, cervical, and rectal secretions. URT immunizations induced high levels of serum neutralizing antibodies (NAbs) against H5 that remained stable out to week 26. The duration of viral shedding correlated with the magnitude of the NAb response at week 26. Adverse events (AEs) were mild, and peak NAb titers were associated with overall AE frequency and duration. Serum NAb titers could be boosted to very high levels 2 to 5 years after Ad4-H5-Vtn vaccination with recombinant H5 or inactivated split H5N1 vaccine. CONCLUSION. Replicating Ad4 delivered to the URT caused prolonged exposure to antigen, drove durable systemic and mucosal immunity, and proved to be a promising platform for the induction of immunity against viral surface glycoprotein targets. TRIAL REGISTRATION. ClinicalTrials.gov NCT01443936 and NCT01806909. FUNDING. Intramural and Extramural Research Programs of the NIAID, NIH (U19 AI109946) and the Centers of Excellence for Influenza Research and Surveillance (CEIRS), NIAID, NIH (contract HHSN272201400008C).
- Open Access
- 3 March 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (4) , 1808-1822
Capsular glycan recognition provides antibody-mediated immunity against tuberculosis
A better understanding of all immune components involved in protecting against Mycobacterium tuberculosis infection is urgently needed to inform strategies for novel immunotherapy and tuberculosis (TB) vaccine development. Although cell-mediated immunity is critical, increasing evidence supports that antibodies also have a protective role against TB. Yet knowledge of protective antigens is limited. Analyzing sera from 97 US immigrants at various stages of M. tuberculosis infection, we showed protective in vitro and in vivo efficacy of polyclonal IgG against the M. tuberculosis capsular polysaccharide arabinomannan (AM). Using recently developed glycan arrays, we established that anti-AM IgG induced in natural infection is highly heterogeneous in its binding specificity and differs in both its reactivity to oligosaccharide motifs within AM and its functions in bacillus Calmette-Guérin vaccination and/or in controlled (latent) versus uncontrolled (TB) M. tuberculosis infection. We showed that anti-AM IgG from asymptomatic but not from diseased individuals was protective and provided data suggesting a potential role of IgG2 and specific AM oligosaccharides. Filling a gap in the current knowledge of protective antigens in humans, our data support the key role of the M. tuberculosis surface glycan AM and suggest the importance of targeting specific glycan epitopes within AM in antibody-mediated immunity against TB.
- 3 March 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (4) , 1808-1822
Open AccessCapsular glycan recognition provides antibody-mediated immunity against tuberculosis
A better understanding of all immune components involved in protecting against Mycobacterium tuberculosis infection is urgently needed to inform strategies for novel immunotherapy and tuberculosis (TB) vaccine development. Although cell-mediated immunity is critical, increasing evidence supports that antibodies also have a protective role against TB. Yet knowledge of protective antigens is limited. Analyzing sera from 97 US immigrants at various stages of M. tuberculosis infection, we showed protective in vitro and in vivo efficacy of polyclonal IgG against the M. tuberculosis capsular polysaccharide arabinomannan (AM). Using recently developed glycan arrays, we established that anti-AM IgG induced in natural infection is highly heterogeneous in its binding specificity and differs in both its reactivity to oligosaccharide motifs within AM and its functions in bacillus Calmette-Guérin vaccination and/or in controlled (latent) versus uncontrolled (TB) M. tuberculosis infection. We showed that anti-AM IgG from asymptomatic but not from diseased individuals was protective and provided data suggesting a potential role of IgG2 and specific AM oligosaccharides. Filling a gap in the current knowledge of protective antigens in humans, our data support the key role of the M. tuberculosis surface glycan AM and suggest the importance of targeting specific glycan epitopes within AM in antibody-mediated immunity against TB.
- 14 June 2019
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (12) , 3589-3601
PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma
Purpose: To evaluate therapeutic activity of PAK inhibition in ATLL and to characterize the role of PAK isoforms in cell proliferation, survival, and adhesion of ATLL cells in preclinical models. Experimental Design: Frequency and prognostic impact of PAK2 amplification were evaluated in an ATLL cohort of 370 cases. Novel long term cultures and in vivo xenograft models were developed using primary ATLL cells from North American patients. Two PAK inhibitors were used to block PAK kinase activity pharmacologically. siRNA-based gene silencing approach was used to genetically knock down (KD) PAK1 and PAK2 in ATLL cell lines. Results: PAK1/2/4 are the three most abundantly expressed PAK family members in ATLL. PAK2 amplifications are seen in 24% of ATLLs and are associated with worse prognosis in a large patient cohort. The pan-PAK inhibitor PF-3758309 (PF) has strong in vitro and in vivo activity in a variety of ATLL preclinical models. These activities of PF are likely attributed to its ability to target several PAK isoforms simultaneously because genetic silencing of either PAK1 or PAK2 produced more modest effects. PAK2 plays a major role in CADM1-mediated stromal interaction, which is an important step in systemic dissemination of the disease. This finding is consistent with the observation that PAK2 amplification is more frequent in aggressive ATLLs and correlates with inferior outcome. Conclusions: PAK2, a gene frequently amplified in ATLL, facilitates CADM1-mediated stromal interaction and promotes survival of ATLL cells. Taken together, PAK inhibition may hold significant promise as a targeted therapy for aggressive ATLLs.
- 14 June 2019
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (12) , 3589-3601
PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma
Purpose: To evaluate therapeutic activity of PAK inhibition in ATLL and to characterize the role of PAK isoforms in cell proliferation, survival, and adhesion of ATLL cells in preclinical models. Experimental Design: Frequency and prognostic impact of PAK2 amplification were evaluated in an ATLL cohort of 370 cases. Novel long term cultures and in vivo xenograft models were developed using primary ATLL cells from North American patients. Two PAK inhibitors were used to block PAK kinase activity pharmacologically. siRNA-based gene silencing approach was used to genetically knock down (KD) PAK1 and PAK2 in ATLL cell lines. Results: PAK1/2/4 are the three most abundantly expressed PAK family members in ATLL. PAK2 amplifications are seen in 24% of ATLLs and are associated with worse prognosis in a large patient cohort. The pan-PAK inhibitor PF-3758309 (PF) has strong in vitro and in vivo activity in a variety of ATLL preclinical models. These activities of PF are likely attributed to its ability to target several PAK isoforms simultaneously because genetic silencing of either PAK1 or PAK2 produced more modest effects. PAK2 plays a major role in CADM1-mediated stromal interaction, which is an important step in systemic dissemination of the disease. This finding is consistent with the observation that PAK2 amplification is more frequent in aggressive ATLLs and correlates with inferior outcome. Conclusions: PAK2, a gene frequently amplified in ATLL, facilitates CADM1-mediated stromal interaction and promotes survival of ATLL cells. Taken together, PAK inhibition may hold significant promise as a targeted therapy for aggressive ATLLs.
- 12 April 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 4 (34)
Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine
Ad4-H5 vaccine induces prolonged increases in H5-specific B cell frequency, antibody affinity, and somatic hypermutation.
- 12 April 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 4 (34)
Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine
Ad4-H5 vaccine induces prolonged increases in H5-specific B cell frequency, antibody affinity, and somatic hypermutation.
- Open Access
- 13 August 2018
- Published by American Society of Hematology in Blood
- Vol. 132 (14) , 1507-1518
North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies
Key Points: North American ATLL has a distinct genomic landscape with a high frequency of prognostic epigenetic mutations, including EP300 mutations. ATLL samples with mutated EP300 have compromised p53 function and are selectively sensitive to decitabine treatment.
- 13 August 2018
- Published by American Society of Hematology in Blood
- Vol. 132 (14) , 1507-1518
Open AccessNorth American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies
Key Points: North American ATLL has a distinct genomic landscape with a high frequency of prognostic epigenetic mutations, including EP300 mutations. ATLL samples with mutated EP300 have compromised p53 function and are selectively sensitive to decitabine treatment.
- Top Cited Papers
Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth